Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Henan Cancer Hospital
Modality
UNKNOWN
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07187908CT.gov Efbemalenograstim Alfa for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermediate Risk of Chemotherapy Regimens Associated With Other Risk Factors in FN | — | Recruiting | — | — | — |
NCT06649448CT.gov A Multi-cohort Study of Efbemalenograstim Alfa Injection for Preventing ANC Reduction in Solid Tumor Patients Post Immune-chemotherapy. | — | Not Yet Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95Indicative
Detailed axis rationale is planned and will be published soon.
Same indication · Neutropenia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Efbemalenograstim Alfa (this asset) | Henan Cancer Hospital | P2 | CCC · 53 |
| f-627 | EVIVE Biotechnology | P3 | BBB |
| Nivestim | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P4 | BBB |
| Pegfilgrastim | Affiliated Hospital of North Sichuan Medical College | P4 | BBB |
| Cefepime | Hospital Universitari Vall d'Hebron Research Institute | P4 | BB |
| Docetaxel | Spectrum Pharmaceuticals, Inc | P3 | BB |
| Spi-2012 | Spectrum Pharmaceuticals, Inc | P3 | BB |
| Cyclophosphamide | Spectrum Pharmaceuticals, Inc | P3 | BB |
| Posaconazole | Merck Sharp & Dohme LLC | P4 | BB |
+42 more in the Neutropenia cohort
Other indications for Efbemalenograstim Alfa
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Cervical Cancer | — | P2 | CCC · 48 |
| Ovarian Cancer | — | P2 | CC · 46 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Efbemalenograstim Alfa in Neutropenia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/efbemalenograstim-alfa-neutropenia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →